BioWorld

June 27, 2006

View Archived Issues

Vasogen Again Battered By Negative Data On Celacade

Poor Celacade data sank shares of Vasogen Inc., though the company s top executive pointed to a bit of silver lining in this story. (BioWorld Today) Read More

Metabolex's Multi-Part Deal With Ortho: $548M Potential

Read More

Anadys Suspending ANA975 Dosing; TLR7's Future Cloudy

Read More

Nastech, Amylin Nasal Byetta Partnership Has $89M Ceiling

Read More

Clinic Roundup

Read More

Other News To Note

Read More